

SANGSTAT MEDICAL CORP  
Form SC TO-T/A  
September 17, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### SCHEDULE TO

Tender Offer Statement Under Section 14(D)(1) Or Section 13(E)(1)  
Of The Securities Exchange Act Of 1934  
FINAL AMENDMENT

### SangStat Medical Corporation

(Name Of Subject Company (Issuer))

### Genzyme Corporation

### Swift Starboard Corporation

(Names of Filing Persons (Offerors))

Common Stock, Par Value \$0.001 per Share  
(Including the Associated Preferred Stock Purchase Rights)

(Title of Class of Securities)

801003104

(CUSIP Number of Class of Securities)

Peter Wirth  
Genzyme Corporation  
One Kendall Square  
Cambridge, MA 02139  
Telephone: (617) 252-7500

(Name, address and telephone number of person authorized  
to receive notices and communications on behalf of filing persons)

with copies to:

Paul Kinsella  
Ropes & Gray LLP  
One International Place  
Boston, Massachusetts 02110  
Telephone: (617) 951-7000

o

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

ý

Edgar Filing: SANGSTAT MEDICAL CORP - Form SC TO-T/A

third-party tender offer subject to Rule 14d-1.

o

issuer tender offer subject to Rule 13e-4.

o

going-private transaction subject to Rule 13e-3.

o

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

This Final Amendment on Schedule TO amends and supplements the Tender Offer Statement on Schedule TO (the "Tender Offer Statement") initially filed with the Securities and Exchange Commission on August 13, 2003 by Genzyme Corporation ("Genzyme") and Swift Starboard Corporation ("Swift"). The Tender Offer Statement relates to a tender offer (the "Offer") by Swift to purchase all the outstanding shares of common stock, par value \$0.001 per share, including the associated preferred stock purchase rights (together, the "Shares"), of SangStat Medical Corporation ("SangStat") at a purchase price of \$22.50 per Share, net to the seller in cash, without interest thereon, upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 13, 2003 and in the related Letter of Transmittal, which are filed as exhibits (a)(1) and (a)(2), respectively, to the Tender Offer Statement. The Offer expired at 12:00 midnight (New York City time) on September 10, 2003.

**ITEM 11. ADDITIONAL INFORMATION**

On September 11, 2003, Genzyme announced in a press release that the Offer expired at 12:00 midnight (New York City time) on September 10, 2003. Based on information provided by the Depository, as of September 15, 2003, 25,454,090 Shares were tendered and not withdrawn, which represents approximately 95% of all outstanding Shares. The Purchaser has accepted for payment the Shares that were validly tendered and not withdrawn.

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GENZYME CORPORATION

Dated: September 17, 2003

By:

/s/ MICHAEL S. WYZGA

Michael S. Wyzga  
*Executive Vice President, Finance and  
Chief Financial Officer*

QuickLinks

ITEM 11. ADDITIONAL INFORMATION

SIGNATURES